Venus Remedies' Q2 FY 2025-26 Quarterly Results

Result Summary

• Venus Remedies Ltd reported a 38.3% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Sep (Q2 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 9.2%.
• Its expenses for the quarter were up by 31.2% QoQ and down 0.6% YoY.
• The net profit increased 109.7% QoQ and increased 471.9% YoY.
• The earnings per share (EPS) of Venus Remedies Ltd stood at 15.06 during Q2 FY 2025-26.

Financial Statments for Q2 FY 2025-26

---

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Venus Remedies Ltd is a pharmaceutical company that specializes in the development and production of a wide range of pharmaceutical formulations. The company operates primarily in the healthcare industry, providing services and products such as injectable antibiotics and other critical care medications. Venus Remedies is known for its focus on research and development, aiming to innovate within the pharmaceutical sector. The company has made significant advances in oncology, antimicrobials, and anti-inflammatory drugs. Recent developments for Venus Remedies include expanding its global presence through strategic alliances and focusing on increasing its product portfolio in key therapeutic segments.

Revenue

In the second quarter of the fiscal year 2026, Venus Remedies Ltd reported a total income of ₹194.46 crores. This represents a notable quarter-over-quarter (QoQ) increase of 38.3% from ₹140.59 crores in the first quarter of FY26. Year-over-year (YoY) analysis shows a growth of 9.2% compared to ₹178.03 crores in the second quarter of FY25. The steady rise in total income indicates an upward trajectory in the company's revenue generation capabilities. This growth can be attributed to factors such as increased sales, expansion into new markets, or enhanced product offerings, though specific drivers are not detailed in the provided data.

Profitability

Profitability metrics for Venus Remedies Ltd in Q2FY26 exhibit significant improvements. The company recorded a profit before tax of ₹26.49 crores, marking an impressive 110.2% QoQ growth from ₹12.60 crores in Q1FY26 and a 191.7% YoY increase from ₹9.08 crores in Q2FY25. Following taxation, the profit after tax for Q2FY26 stood at ₹20.13 crores, which is 109.7% higher than the previous quarter's ₹9.60 crores and 471.9% above the ₹3.52 crores reported in Q2FY25. Earnings per share also reflected this positive trend, rising to ₹15.06 from ₹7.18 in Q1FY26 and ₹2.63 in Q2FY25, paralleling the growth in profit after tax.

Operating Metrics

The operating expenses for Venus Remedies Ltd in Q2FY26 were ₹167.97 crores, which is a 31.2% increase from ₹127.99 crores in Q1FY26, but a slight decrease of 0.6% compared to ₹168.96 crores in Q2FY25. The notable increase in expenses QoQ may reflect strategic investments in production or expansion initiatives. Despite the rise in expenses, the company managed to achieve substantial profitability growth, indicating effective cost management strategies. The tax payable also increased significantly by 112.0% QoQ from ₹3.00 crores in Q1FY26 to ₹6.36 crores in Q2FY26, reflecting the higher profitability levels. Year-over-year, the tax increased by 14.4% from ₹5.56 crores in Q2FY25.